JP2019508714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508714A5 JP2019508714A5 JP2018555442A JP2018555442A JP2019508714A5 JP 2019508714 A5 JP2019508714 A5 JP 2019508714A5 JP 2018555442 A JP2018555442 A JP 2018555442A JP 2018555442 A JP2018555442 A JP 2018555442A JP 2019508714 A5 JP2019508714 A5 JP 2019508714A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- amount
- bcma polypeptide
- subject
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 68
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 66
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 66
- 239000012634 fragment Substances 0.000 claims description 64
- 229920001184 polypeptide Polymers 0.000 claims description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 37
- 239000012472 biological sample Substances 0.000 claims description 30
- 238000003556 assay Methods 0.000 claims description 25
- 239000000523 sample Substances 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 24
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 10
- 210000001185 bone marrow Anatomy 0.000 claims description 10
- 210000005087 mononuclear cell Anatomy 0.000 claims description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 206010061598 Immunodeficiency Diseases 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 230000007813 immunodeficiency Effects 0.000 claims description 8
- 238000003127 radioimmunoassay Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 210000000987 immune system Anatomy 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 claims description 5
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 4
- 238000012286 ELISA Assay Methods 0.000 claims description 4
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 4
- 208000009388 Job Syndrome Diseases 0.000 claims description 4
- 230000001010 compromised effect Effects 0.000 claims description 4
- 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 claims description 4
- 206010051040 hyper-IgE syndrome Diseases 0.000 claims description 4
- 208000012116 immunodeficiency-related disease Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 2
- 208000033241 Autosomal dominant hyper-IgE syndrome Diseases 0.000 claims description 2
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 claims description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 claims description 2
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 claims description 2
- 208000003352 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 claims description 2
- 208000007924 IgA Deficiency Diseases 0.000 claims description 2
- 101150105931 LRBA gene Proteins 0.000 claims description 2
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 claims description 2
- 206010039915 Selective IgA immunodeficiency Diseases 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000002388 complement deficiency Diseases 0.000 claims description 2
- 206010066130 hyper-IgM syndrome Diseases 0.000 claims description 2
- 230000000521 hyperimmunizing effect Effects 0.000 claims description 2
- 201000007156 immunoglobulin alpha deficiency Diseases 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 208000029138 selective IgA deficiency disease Diseases 0.000 claims description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims description 2
- 208000008732 thymoma Diseases 0.000 claims description 2
- 208000023706 Bruton agammaglobulinaemia Diseases 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 208000029192 congenital agammaglobulinemia Diseases 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- 208000035623 congenital anemia Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022004416A JP2022058619A (ja) | 2016-01-12 | 2022-01-14 | 被験体の免疫状態をモニタリングするための改善された方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277801P | 2016-01-12 | 2016-01-12 | |
| US62/277,801 | 2016-01-12 | ||
| US201662300708P | 2016-02-26 | 2016-02-26 | |
| US62/300,708 | 2016-02-26 | ||
| PCT/US2017/013169 WO2017123741A1 (en) | 2016-01-12 | 2017-01-12 | Improved methods for monitoring immune status of a subject |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022004416A Division JP2022058619A (ja) | 2016-01-12 | 2022-01-14 | 被験体の免疫状態をモニタリングするための改善された方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019508714A JP2019508714A (ja) | 2019-03-28 |
| JP2019508714A5 true JP2019508714A5 (enExample) | 2020-02-27 |
| JP7011600B2 JP7011600B2 (ja) | 2022-01-26 |
Family
ID=59312140
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555442A Active JP7011600B2 (ja) | 2016-01-12 | 2017-01-12 | 被験体の免疫状態をモニタリングするための改善された方法 |
| JP2022004416A Pending JP2022058619A (ja) | 2016-01-12 | 2022-01-14 | 被験体の免疫状態をモニタリングするための改善された方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022004416A Pending JP2022058619A (ja) | 2016-01-12 | 2022-01-14 | 被験体の免疫状態をモニタリングするための改善された方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11698369B2 (enExample) |
| EP (2) | EP3402515B8 (enExample) |
| JP (2) | JP7011600B2 (enExample) |
| DK (1) | DK3402515T3 (enExample) |
| ES (1) | ES2898329T3 (enExample) |
| WO (1) | WO2017123741A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
| EP3639028B1 (en) | 2017-06-13 | 2025-10-15 | Onco Tracker, Inc. | Diagnostic, prognostic, and monitoring methods for breast cancer |
| CN112703204B (zh) * | 2018-09-28 | 2024-10-01 | 安进公司 | 针对可溶性bcma的抗体 |
| CA3178882A1 (en) | 2020-05-08 | 2021-11-11 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
| CN118206620A (zh) * | 2022-12-09 | 2024-06-18 | 上海细胞治疗集团股份有限公司 | 一种多肽标签及其应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4493795A (en) | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| CA2260014A1 (en) | 1996-07-10 | 1998-01-15 | Meiji Milk Products Co., Ltd. | Novel use of mk family as hematopoietic factor |
| GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6355623B2 (en) | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| AU2002306596B2 (en) | 2001-02-27 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| WO2003022877A1 (en) | 2001-09-06 | 2003-03-20 | Biogen Idec Ma Inc. | Crystal structure of baff, and use thereof in drug design |
| AU2004220078A1 (en) | 2003-03-07 | 2004-09-23 | Xencor, Inc | BAFF mutants with at least one amino acid substitution and methods of their production |
| JP5570681B2 (ja) | 2004-08-31 | 2014-08-13 | 興和株式会社 | 抗ヒトｂａｆｆ抗体 |
| CA2583900A1 (en) | 2004-10-13 | 2006-04-27 | The Washington University | Use of baff to treat sepsis |
| US7947805B2 (en) * | 2004-12-23 | 2011-05-24 | Merck Serono S.A. | BCMA polypeptides and uses thereof |
| WO2007053732A2 (en) | 2005-11-01 | 2007-05-10 | Mayo Foundation For Medical Education And Research | Promoter polymorphisms of the blys gene and use in diagnostic methods |
| US8202698B2 (en) | 2005-11-08 | 2012-06-19 | Biogen Idec Ma Inc. | Methods of evaluating BAFF |
| US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
| SI1966202T1 (sl) | 2005-12-13 | 2012-01-31 | Incyte Corp | S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze |
| US20080058316A1 (en) | 2006-02-27 | 2008-03-06 | The Johns Hopkins University | Cancer treatment with gama-secretase inhibitors |
| ES2382777T3 (es) | 2006-05-03 | 2012-06-13 | Government Of The United States Of America,As Represented By The Secretary, Department Of Health And Human Services | Receptor de células T quimérico y materiales relacionados y métodos de uso |
| EP4606378A3 (en) | 2007-06-13 | 2025-11-05 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-( 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3- cyclopentylprop anenitrile |
| AU2009239437B2 (en) | 2008-04-25 | 2014-11-13 | University Of Washington | Levels of BCMA protein expression on B cells and use in diagnostic methods |
| HUE029619T4 (en) * | 2009-03-10 | 2017-07-28 | Biogen Ma Inc | Anti-bcma antibodies |
| US9101559B2 (en) | 2009-05-08 | 2015-08-11 | New York University | Leukemic cell CNS infiltration controlled by notch-induced chemotaxis |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| CA2833820C (en) | 2011-05-27 | 2019-10-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| CA2889764C (en) * | 2012-11-01 | 2023-10-10 | Martin Lipp | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| US20160331754A1 (en) | 2014-01-20 | 2016-11-17 | Gilead Sciences, Inc. | Therapies for treating cancers |
| KR102526945B1 (ko) | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| EP4233870A3 (en) | 2014-05-28 | 2024-01-24 | Onco Tracker, Inc. | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| EP3154596A4 (en) | 2014-06-10 | 2018-01-24 | Institute for Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
| PL3179992T3 (pl) | 2014-08-11 | 2022-08-16 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora BTK, inhibitora PD-1 i/lub inhibitora PD-L1 |
| ES2952717T3 (es) | 2014-10-14 | 2023-11-03 | Novartis Ag | Moléculas de anticuerpos contra PD-L1 y usos de las mismas |
| CN113603795A (zh) | 2014-12-05 | 2021-11-05 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| EP3271483B1 (en) | 2015-03-17 | 2021-07-21 | Mayo Foundation for Medical Education and Research | Methods and materials for assessing and treating cancer |
| SG10201913841SA (en) | 2015-07-24 | 2020-03-30 | Oncotracker Inc | Gamma secretase modulators for the treatment of immune system dysfunction |
| UA127515C2 (uk) | 2015-08-17 | 2023-09-20 | Янссен Байотек, Інк. | Антитіло до всма, біспецифічна антигензв'язувальна молекула, що зв'язує всма і cd3, і їх використання |
| AU2016347516A1 (en) * | 2015-10-30 | 2018-05-10 | Glaxosmithkline Intellectual Property Development Limited | Prognostic method |
| DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
| EP3458853B1 (en) | 2016-05-16 | 2022-09-07 | Onco Tracker, Inc. | Improved methods for monitoring immune status of a subject |
| RU2019105693A (ru) | 2016-08-01 | 2020-09-01 | Новартис Аг | Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага |
| WO2018085363A2 (en) | 2016-11-02 | 2018-05-11 | Berenson James Richard | Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma |
| EP3639028B1 (en) | 2017-06-13 | 2025-10-15 | Onco Tracker, Inc. | Diagnostic, prognostic, and monitoring methods for breast cancer |
| JP2020528885A (ja) | 2017-07-19 | 2020-10-01 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| WO2020092792A2 (en) | 2018-10-31 | 2020-05-07 | Oncotracker, Inc. | Method of enhancing immune-based therapy |
-
2017
- 2017-01-12 DK DK17738918.6T patent/DK3402515T3/da active
- 2017-01-12 EP EP17738918.6A patent/EP3402515B8/en active Active
- 2017-01-12 WO PCT/US2017/013169 patent/WO2017123741A1/en not_active Ceased
- 2017-01-12 JP JP2018555442A patent/JP7011600B2/ja active Active
- 2017-01-12 ES ES17738918T patent/ES2898329T3/es active Active
- 2017-01-12 US US16/068,831 patent/US11698369B2/en active Active
- 2017-01-12 EP EP21190326.5A patent/EP4079320A1/en active Pending
-
2022
- 2022-01-14 JP JP2022004416A patent/JP2022058619A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508714A5 (enExample) | ||
| JP2016507066A5 (enExample) | ||
| US9651563B2 (en) | Biomarkers for liver fibrosis | |
| Dowling et al. | 2‐D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins | |
| Ankerhold et al. | Circulating multimeric immune complexes contribute to immunopathology in COVID-19 | |
| US20090226905A1 (en) | Diagnosis and prognosis of colorectal cancer | |
| JP2014509853A5 (enExample) | ||
| EP2952896B1 (en) | Method for reducing false negatives in immunoassay for assaying biomembrane-derived specimen | |
| JP2019023645A5 (enExample) | ||
| JP2017514142A (ja) | Ｈｐｖ関連症状のための新規な方法、バイオアッセイ及びバイオマーカー | |
| JP2010536043A5 (enExample) | ||
| JP2017532544A5 (enExample) | ||
| US20180017554A1 (en) | Marker sequences for the diagnosis and stratification of systemic sclerosis patients | |
| JP2019531716A5 (enExample) | ||
| CN104126124A (zh) | 用于慢性hbv患者的反应预测和疗法监测的hbv免疫复合物 | |
| US20150044666A1 (en) | Non-equilibrium two-site assays for linear, ultrasensitive analyte detection | |
| Kouwaki et al. | K63‐linked polyubiquitination of LGP2 by Riplet regulates RIG‐I‐dependent innate immune response | |
| CN115754291B (zh) | 肝细胞癌的早期检测 | |
| JP2014524583A5 (enExample) | ||
| US20170320921A1 (en) | Protein m related immunoglobulin-binding polypeptides | |
| Marin et al. | Identification of SARS-CoV-2 biomarkers in saliva by transcriptomic and proteomics analysis | |
| Kaysheva et al. | Mass spectrometric detection of the amino acid sequence polymorphism of the hepatitis C virus antigen | |
| EP3008469B1 (en) | Methods for predicting rheumatoid arthritis treatment response | |
| CN110114676A (zh) | 肾素浓度的免疫学测定方法 | |
| WO2017065261A1 (ja) | ヒトパルボウイルスｂ１９抗原および抗体の同時検出方法及びキット |